Myomo reports Q4 EPS (9c), consensus (9c)

Reports Q4 revenue $11.4M, consensus $10.4M. “We delivered 2025 revenue at the midpoint of our updated guidance range with record fourth quarter revenues from the U.S. orthotics and prosthetics and International sales channels. We also achieved our strongest quarter of the year for MyoPro authorizations and orders,” said Paul Gudonis, Myomo’s (MYO) Chairman and Chief Executive Officer. “We look forward to improved results from our 2026 marketing initiatives as we place greater emphasis on referrals and other recurring patient sources with a lower customer acquisition cost.”